Judy M Coulson

List of Publications by Year
in descending order

43 papers	2,129 citations	257450 24 h-index	289244 40 g-index
45 all docs	45 docs citations	45 times ranked	3768 citing authors

#	Article	IF	Citations
1	Aggressive uveal melanoma displays a high degree of centrosome amplification, opening the door to therapeutic intervention. Journal of Pathology: Clinical Research, 2022, 8, 383-394.	3.0	2
2	Loss of <i>BAP1</i> expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. Journal of Pathology, 2020, 250, 420-439.	4.5	97
3	Isoform-specific Ras signaling is growth factor dependent. Molecular Biology of the Cell, 2019, 30, 1108-1117.	2.1	23
4	Targeting centrosome amplification, an Achilles' heel of cancer. Biochemical Society Transactions, 2019, 47, 1209-1222.	3.4	40
5	The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity. Oncogene, 2018, 37, 2326-2342.	5.9	29
6	Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. Journal of Pathology: Clinical Research, 2018, 4, 26-38.	3.0	55
7	New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. Cancer Research, 2018, 78, 15-29.	0.9	124
8	Kinomeâ€wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. Pigment Cell and Melanoma Research, 2018, 31, 253-266.	3.3	11
9	SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance. EBioMedicine, 2018, 38, 113-126.	6.1	66
10	RAS variant signalling. Biochemical Society Transactions, 2018, 46, 1325-1332.	3.4	61
11	Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?. Future Oncology, 2018, 14, 1335-1338.	2.4	21
12	Quantification of spatiotemporal patterns of Ras isoform expression during development. Scientific Reports, 2017, 7, 41297.	3.3	45
13	Regulation of the cell cycle and centrosome biology by deubiquitylases. Biochemical Society Transactions, 2017, 45, 1125-1136.	3.4	30
14	Transcriptomic and epigenetic regulation of disuse atrophy and the return to activity in skeletal muscle. FASEB Journal, 2017, 31, 5268-5282.	0.5	51
15	Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. Journal of Proteome Research, 2015, 14, 5263-5272.	3.7	12
16	Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget, 2015, 6, 13757-13771.	1.8	48
17	Decoding RAS isoform and codon-specific signalling. Biochemical Society Transactions, 2014, 42, 742-746.	3.4	14
18	Plasticity of Mammary Cell Boundaries Governed by EGF and Actin Remodeling. Cell Reports, 2014, 8, 1722-1730.	6.4	11

#	Article	IF	Citations
19	Deubiquitylases From Genes to Organism. Physiological Reviews, 2013, 93, 1289-1315.	28.8	350
20	The deubiquitylase USP15 stabilizes newly synthesized REST and rescues its expression at mitotic exit. Cell Cycle, 2013, 12, 1964-1977.	2.6	44
21	Cellular functions of the DUBs. Journal of Cell Science, 2012, 125, 277-286.	2.0	188
22	Direct and Indirect Control of Mitogen-activated Protein Kinase Pathway-associated Components, BRAP/IMP E3 Ubiquitin Ligase and CRAF/RAF1 Kinase, by the Deubiquitylating Enzyme USP15. Journal of Biological Chemistry, 2012, 287, 43007-43018.	3.4	44
23	Isoformâ€Specific Localization of the Deubiquitinase USP33 to the Golgi Apparatus. Traffic, 2011, 12, 1563-1574.	2.7	24
24	Emerging roles of deubiquitinases in cancerâ€associated pathways. IUBMB Life, 2010, 62, 140-157.	3.4	141
25	SCG3 Transcript in Peripheral Blood Is a Prognostic Biomarker for REST-Deficient Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 274-283.	7.0	50
26	Reduction in RNA Levels Rather than Retardation of Translation Is Responsible for the Inhibition of Major Histocompatibility Complex Class I Antigen Presentation by the Glutamic Acid-Rich Repeat of Herpesvirus Saimiri Open Reading Frame 73. Journal of Virology, 2009, 83, 273-282.	3.4	10
27	Realâ€time Polymerase Chain Reaction to Follow the Response of Muscle to Training. Artificial Organs, 2008, 32, 630-633.	1.9	2
28	Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER. Cancer Immunology, Immunotherapy, 2007, 56, 1143-1152.	4.2	17
29	Site-specific phosphorylation of SCG10 in neuronal plasticity: Role of Ser73 phosphorylation by N-methyl d-aspartic acid receptor activation in rat hippocampus. Neuroscience Letters, 2006, 396, 241-246.	2.1	14
30	Transcriptional Regulation: Cancer, Neurons and the REST. Current Biology, 2005, 15, R665-R668.	3.9	153
31	Roles for USF-2 in lung cancer proliferation and bronchial carcinogenesis. Journal of Pathology, 2005, 206, 151-159.	4.5	26
32	Regulation of the Cell-specific Calcitonin/Calcitonin Gene-related Peptide Enhancer by USF and the Foxa2 Forkhead Protein. Journal of Biological Chemistry, 2004, 279, 49948-49955.	3.4	20
33	Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases. International Journal of Cancer, 2004, 110, 891-895.	5.1	23
34	Neuroendocrine Phenotype of Small Cell Lung Cancer. , 2003, 74, 61-74.		9
35	Detection of Small Cell Lung Cancer by RT-PCR for Neuropeptides, Neuropeptide Receptors, or a Splice Variant of the Neuron Restrictive Silencer Factor. , 2003, 75, 335-352.		8
36	Cross-talk between hypoxic and circadian pathways: cooperative roles for hypoxia-inducible factor 1Î± and CLOCK in transcriptional activation of the vasopressin gene. Molecular and Cellular Neurosciences, 2003, 22, 396-404.	2.2	49

#	Article	IF	Citations
37	Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box. Biochemical Journal, 2003, 369, 549-561.	3.7	25
38	Studies on the Expression of Endothelin, Its Receptor Subtypes, and Converting Enzymes in Lung Cancer and in Human Bronchial Epithelium. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 422-431.	2.9	93
39	E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochemical Journal, 1999, 344, 961-970.	3.7	27
40	E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer. Biochemical Journal, 1999, 344, 961.	3.7	9
41	A novel method to stabilise antisense oligonucleotides against exonuclease degradation. Nucleic Acids Research, 1993, 21, 2957-2958.	14.5	56
42	Applications of antisense oligodeoxynucleotides in virology. Biochemical Society Transactions, 1992, 20, 762-764.	3.4	5
43	Antisense Oligonucleotides as Antiviral Agentsa. Annals of the New York Academy of Sciences, 1992, 660, 339-341.	3.8	2